Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
CEACAM1 shows up in 90% of mantle cell lymphoma cases — far more than other blood cancers — making it a compelling new therapeutic target. Researchers say it could be addressed with ADCs, bispecific antibodies, or CAR T-cell therapies. This is especially relevant for patients who've exhausted BTK inhibitor and CD19/CD20-directed treatments.
Mantle cell lymphoma (MCL) is aggressive and prone to relapse, and patients who exhaust standard therapies often have few options left. But a new retrospective study is shining a spotlight on CEACAM1 — a cell surface protein that appears in 90% of MCL cases — as a promising new therapeutic target.
Compared to just 35% expression across other lymphoma subtypes, CEACAM1's near-ubiquitous presence in MCL creates a clear opportunity for targeted therapies like antibody-drug conjugates (ADCs), bispecific antibodies, and potentially CAR T-cell approaches. Researchers note it's particularly relevant for patients who've progressed on BTK inhibitors or lost CD19/CD20 expression — scenarios that currently leave clinicians with very limited treatment options.
By the Numbers:
Why it matters: As CD19- and CD20-directed therapies become standard, antigen loss is a growing concern. CEACAM1 could serve as a backup target — and potentially a frontline one — giving oncologists a new tool to fight one of the trickiest lymphomas out there.
